Malaria vaccine is under clinical development by Expres2ion Biotechnologies and currently in Phase II for Malaria. According to GlobalData, Phase II drugs for Malaria have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Malaria vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Malaria vaccine overview
Vaccine is under development for the prevention of malaria. It is a second-generation RH5 vaccine, RH5.2, in S2 insect cells. RH5.2 is engineered to retain regions important for red blood cell recognition, which are targeted by neutralising antibodies. The RH5.2 protein is displayed on the surface of a hepatitis B derived virus-like particle (VLP). It is administered through intramuscular route.
Expres2ion Biotechnologies overview
Expres2ion Biotechnologies (Expres2ion), a subsidiary of ExpreS2ion Biotech Holding AB, is a pharmaceutical company. It discovered and developed the technology platform ExpreS for optimal discovery, preclinical development and GMP production of hard-to-express proteins used in vaccines and vaccine-like treatments. Expres2ion utilizes its S2 recombinant protein technology for use in preclinical development and in clinical trials. Its platform indication includes Breast cancer, Breast cancer and cytomegalovirus, among others. The company also collaborates on various projects, including several malaria vaccines, and offers a range of protein expression and production services from discovery to pre-clinical development and cGMP production. Expres2ion is headquartered in Horsholm, Denmark.
For a complete picture of Malaria vaccine’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
